20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
The 2022 Parkinson’s drug development pipeline report
The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.
Parkinson’s Clinical Study Group
Cure Parkinson’s is funding Professor Oliver Bandmann at the University of Sheffield to establish a nationwide infrastructure for a study group focused specifically on conducting clinical trials for Parkinson’s.
2022 Gulls’ Eggs Luncheon raises over £90k for Parkinson’s research
On Tuesday 10 May, the City’s leading wealth management professionals gathered in the historic Merchant Taylors’ Hall for the 34th annual Gulls’ Eggs Luncheon, raising over £72k for Parkinson’s research.
Phase 1a trial findings of iLCT prioritised drug, Anle138b
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps together in Parkinson’s.
Our Spring Newsletter
Download your interactive PDF copy here now!